Journal of the National Comprehensive Cancer Network
Infectious Complications Associated With Immunomodulating Monoclonal Antibodies Used in the Treatment of Hematologic Malignancy CME

Disclosures

Release Date: March 3, 2008; Valid for credit through March 3, 2009
Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

Contents of This CME Activity
    To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

  1. Infectious Complications Associated With Immunomodulating Monoclonal Antibodies Used in the Treatment of Hematologic Malignancy
    Sophia Koo, MD
    Lindsey R. Baden, MD

Go to Test Questions

 
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Copyright © 2008 Medscape.

 
Medscape
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Describe the actions of rituximab when used for hematologic malignancy
  2. Identify the US Food and Drug Administration (FDA)-approved indication for alemtuzumab for hematologic malignancy
  3. List infectious complications associated with use of alemtuzumab
  4. List major toxicities of gemtuzumab
  5. Describe the incidence of serious infections in patients using infliximab and adalimumab
Authors and Disclosures

Sophia Koo, MD
Disclosure: Sophia Koo, MD, has disclosed no relevant financial relationships.


Lindsey R. Baden, MD
Disclosure: Lindsey R. Baden, MD, has disclosed no relevant financial relationships.


Désirée Lie, MD, MSEd
Disclosure: Désirée Lie, MD, MSEd, has disclosed no relevant financial relationships.


Brahm Segal, MD
Disclosure: Brahm Segal, MD, has disclosed that he has served on the speaker's bureau for Merck and Pfizer and has served on the advisory board for Pfizer.


Alison G. Freifeld, MD
Disclosure: Alison G. Freifeld, MD, has disclosed that she has accepted financial support in the form of research support, advisory committee membership, or speaker's bureau participation from Genzyme Pharmaceuticals, Schering-Plough Corporation, Enzon Pharmaceuticals, and Astellas Pharma, Inc.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.